A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)

What is the purpose of this trial?

Brief Summary:

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.


Participation Guidelines

Ages: 18 - 70 years

Gender: Both


Eli Lilly and Company

Start Date: 01/03/2019

End Date: 12/31/2018

Last Updated: 02/06/2019

Study HIC#: 2000023903

Get Involved

For more information about this study, contact:
Rebecca Chawarski
+1 203-737-8085
rebecca.chawarski@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigator

Brett King

Principal Investigator